Skip to main content

Table 1 Baseline characteristics

From: Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer

   No. %
Healthy volunteers (n = 15)   
 Age median, range 63 27-77
 Sex Male 7 46.7
Female 8 53.3
Non-cancerous patients (n = 11)   
 Age median, range 53 35-79
 Sex Male 7 63.6
Female 4 36.4
Gastric cancer patients (n = 55)   
 Age median, range 58 25-75
 Sex Male 36 65.5
Female 19 34.5
 Disease presentation Recurrent 14 25.5
Metastatic 41 74.5
 Type of surgery Total gastrectomy 9 16.4
Subtotal gastrectomy 10 18.2
No 36 65.5
 Differentiation WD 3 5.5
MD 9 16.4
PD 27 49.1
SRC 12 21.8
Othersa 4 7.3
 Lauren Intestinal 7 12.7
Diffuse 10 18.2
Mixed 1 1.8
Unknown 37 67.3
 HER2 Negative 46 83.6
Positive 8 14.5
Unknown 1 1.8
 Type of body fluid Ascites 46 83.6
Pleural fluid 9 16.4
 Previous palliative chemotherapy at acquisition of body fluid Chemotherapy-naïve 11 20.0
1 14 25.5
2 15 27.3
≥3 15 27.3
  1. WD Well differentiated, MD Moderate differentiated, PD Poorly differentiated, SRC Signet ring cell carcinoma, No Number
  2. Othersa: mucinous adenocarcinoma, undifferentiated carcinoma